KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBIT Margin: 2017-2025

Historic EBIT Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -89.63%.

  • Aquestive Therapeutics' EBIT Margin fell 2841.00% to -89.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 424.07%, marking a year-over-year increase of 45990.00%. This contributed to the annual value of -3,052.68% for FY2024, which is 302282.00% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' EBIT Margin is -89.63%, which was up 21.13% from -113.65% recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year EBIT Margin high stood at 30.39% for Q4 2024, and its period low was -325.85% during Q2 2021.
  • Moreover, its 3-year median value for EBIT Margin was -41.36% (2023), whereas its average is -59.21%.
  • Over the last 5 years, Aquestive Therapeutics' EBIT Margin had its largest YoY gain of 28,456bps in 2021, and its largest YoY loss of 40,485bps in 2021.
  • Over the past 5 years, Aquestive Therapeutics' EBIT Margin (Quarterly) stood at -105.33% in 2021, then spiked by 504bps to -100.29% in 2022, then surged by 7,067bps to -29.62% in 2023, then surged by 6,000bps to 30.39% in 2024, then crashed by 2,841bps to -89.63% in 2025.
  • Its EBIT Margin stands at -89.63% for Q3 2025, versus -113.65% for Q2 2025 and -222.08% for Q1 2025.